0
Skip to Content
Luxa Biotechnology, LLC
Home
About Us
Vision & Mission
Leadership
Our Treatment
Press Releases & Announcements
Contact Us
Luxa Biotechnology, LLC
Home
About Us
Vision & Mission
Leadership
Our Treatment
Press Releases & Announcements
Contact Us
Home
About Us
Vision & Mission
Leadership
Our Treatment
Press Releases & Announcements
Contact Us
Featured
Interview with Luxa Biotechnology Leadership: Promising Results of RPESC-RPE-4W for Dry AMD
May 12, 2025
press release
Interview with Luxa Biotechnology Leadership: Promising Results of RPESC-RPE-4W for Dry AMD
May 12, 2025
press release
Read More →
May 12, 2025
press release
Luxa to Present Phase 1/2a Clinical and Preclinical Data on RPESC-RPE-4W Therapy for Dry AMD at 2025 ARVO Annual Meeting
Apr 29, 2025
press release
Luxa to Present Phase 1/2a Clinical and Preclinical Data on RPESC-RPE-4W Therapy for Dry AMD at 2025 ARVO Annual Meeting
Apr 29, 2025
press release
Read More →
Apr 29, 2025
press release
Luxa Biotechnology Presents Clinical Data from First-in-Human Retinal Pigment Epithelium Cell Therapy Trial for Dry Age-Related Macular Degeneration at the 77th Annual Wills Eye Conference
Mar 9, 2025
press release
Luxa Biotechnology Presents Clinical Data from First-in-Human Retinal Pigment Epithelium Cell Therapy Trial for Dry Age-Related Macular Degeneration at the 77th Annual Wills Eye Conference
Mar 9, 2025
press release
Read More →
Mar 9, 2025
press release
Luxa's stem cell therapy for dry AMD shows early promise
Mar 6, 2025
press release
Luxa's stem cell therapy for dry AMD shows early promise
Mar 6, 2025
press release
Read More →
Mar 6, 2025
press release
Luxa Biotechnology Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to RPESC-RPE-4W Transplantation for the Treatment of Dry Age-Related Macular Degeneration
Feb 19, 2025
press release
Luxa Biotechnology Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to RPESC-RPE-4W Transplantation for the Treatment of Dry Age-Related Macular Degeneration
Feb 19, 2025
press release
Read More →
Feb 19, 2025
press release
Luxa Biotechnology LLC Appoints Keith E. Dionne, Ph.D., as Chief Executive Officer
Oct 1, 2024
press release
Luxa Biotechnology LLC Appoints Keith E. Dionne, Ph.D., as Chief Executive Officer
Oct 1, 2024
press release
Read More →
Oct 1, 2024
press release
Luxa Biotechnology Receives $4 Million Grant for Clinical Trial of Dry AMD Treatment
May 2, 2024
press release
Luxa Biotechnology Receives $4 Million Grant for Clinical Trial of Dry AMD Treatment
May 2, 2024
press release
Read More →
May 2, 2024
press release
Luxa Biotechnology announces paper on 'Identification of Biomarkers for Diversity and Transplantation Efficacy of Retinal Pigment Epithelial Cells' by Dr. Sally Temple.
Jan 23, 2024
press release
Luxa Biotechnology announces paper on 'Identification of Biomarkers for Diversity and Transplantation Efficacy of Retinal Pigment Epithelial Cells' by Dr. Sally Temple.
Jan 23, 2024
press release
Read More →
Jan 23, 2024
press release
Luxa Biotechnology to Provide Update on Clinical Trial of Retinal Pigmented Epithelium Stem Cell (RPESC) Technology for Treatment of Dry Age-Related Macular Degeneration in Panel Session at ARVO
Jan 23, 2024
press release
Luxa Biotechnology to Provide Update on Clinical Trial of Retinal Pigmented Epithelium Stem Cell (RPESC) Technology for Treatment of Dry Age-Related Macular Degeneration in Panel Session at ARVO
Jan 23, 2024
press release
Read More →
Jan 23, 2024
press release
The Report of the Annual Meeting hosted by the National Eye Institute in the United States has been released
Jan 23, 2024
press release
The Report of the Annual Meeting hosted by the National Eye Institute in the United States has been released
Jan 23, 2024
press release
Read More →
Jan 23, 2024
press release

QUICK LINKS

About Us
Vision & Mission
Leadership

Our Treatment

Press Release

Contact Us

CONTACT US

2050 Center Ave, Suite 435, Fort Lee,
NJ 07024 USA

+1 (201) 482-4093
admin@luxabiotech.com

FOLLOW US

Design by Mediaspace.